BEVYXXA is a factor Xa (FXa) inhibitor indicated for the prophylaxis of venous thromboembolism (VTE) in adult patients hospitalized for an acute medical illness who are at risk for thromboembolic complications due to
moderate or severe restricted mobility and other risk factors for VTE.

Most common adverse reaction (incidence >5%) is bleeding.

• P-gp inhibitors increase the blood levels of betrixaban. Reduce BEVYXXA dose.
• Anticoagulants: Avoid concomitant use.

• Risk of Bleeding: Can cause serious, potentially fatal bleeding. Promptly evaluate signs and symptoms of blood loss.
• Severe Renal Impairment: Increased risk of bleeding events; reduce BEVYXXA dose
• Concomitant P-gp Inhibitors: Increased risk of bleeding events; reduce BEVYXXA dose